White Kratom (wild harvested, horn strain)
Mental Energy | Focus & Clarity | Stress Relief | Mood Enhancer
Borneo Energy all time favourite. Now in superfine powder. Our Kratom is 100% wild grown organic Mitragyna Speciosa from Kapuas Hulu region in the West-Kalimantan region of Borneo. The only wild harvested Kratom on the market. Tested and proven to be the most potent of them all, with the highest alkaloid levels compared to all other Kratom out there.
100g - $14 | 200g - $22 | 500g - $39 | 1kg - $70 | 5kg - $320
We give you the real price. No middle men. We are The Source.
Please note: we may need to send your Kratom order in a package without our brand label or in another package due to the packaging regulations on Kratom in Indonesia.
Today there is already a thriving worldwide market for Kratom, a Southeast Asian herb. Kratom has also come onto the radar of the FDA and DEA, who would like to regulate it (it currently is essentially unregulated, except as a supplement). This has sparked a controversy over whether and how Kratom should be regulated, fueled partly by a lack of clear scientific studies.
Horn Kratom trees grow in specific areas in Borneo where the leaves develop little “horns” and have an unusual shape compared to other Kratom. This could happen due to different kind of mineral composition in the soil and other kind of environment for the tree. Many experienced Kratom users are reporting that this type of “Horned” Kratom gives the best effect for them.
Mitragyna speciosa is a tropical evergreen tree in the coffee family native to Southeast Asia.
It produces alkaloid chemicals, mitragynine and 7-hydroxymitragynine (7-HMG), among other compounds. The leaves are traditionally consumed either raw or as a tea, but they can also be smoked, or concentrated into capsules or liquid. The local name for the leaves is kratom or biak. Kratom is used for fatigue, as a pain reliever, and a mood enhancer.
It has been known since 1996 that kratom has opioid effects – mitragynine binds at opioid receptors, which means it has at least some of the effects of opioid drugs like morphine. This is part of the controversy, as the FDA is using this fact as justification for tighter regulation. It is true, however, that mitragynine likely binds only weakly to the opioid receptors, and perhaps to only a subset of receptors.